

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1.– 116. (cancelled)

117. (new) A pharmaceutical dosage form which comprises (a) a first drug which comprises at least one morphine derivative having antitussive activity and (b) at least one second drug, wherein a plasma half-life of the at least one second drug differs from a plasma half-life of the first drug and wherein the dosage form provides a plasma concentration within a therapeutic range of the at least one second drug over a period which is coextensive with at least about 70 % of a period over which the dosage form provides a plasma concentration within a therapeutic range of the first drug.

118. (new) The dosage form of claim 117, wherein the at least one of morphine derivative comprises at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof.

119. (new) The dosage form of claim 118, wherein the first drug comprises at least one of codeine phosphate, dihydrocodeine bitartrate and hydrocodone bitartrate.

120. (new) The dosage form of claim 118, wherein the first drug comprises codeine phosphate.

P24615.A17

121. (new) The dosage form of claim 118, wherein the at least one second drug comprises at least one of a decongestant, expectorant, mucus thinning drug, and antihistamine.

122. (new) The dosage form of claim 117, wherein the at least one second drug comprises a decongestant.

123. (new) The dosage form of claim 122, wherein the second drug comprises at least one of phenylephrine, pseudoephedrine and pharmaceutically acceptable salts thereof.

124. (new) The dosage form of claim 118, wherein the at least one second drug comprises an antihistamine.

125. (new) The dosage form of claim 124, wherein the antihistamine comprises at least one of chlorpheniramine, promethazine, carbinoxamine and pharmaceutically acceptable salts thereof.

126. (new) The dosage form of claim 117, wherein the at least one second drug comprises an expectorant.

127. (new) The dosage form of claim 126, wherein the expectorant comprises guaifenesin.

128. (new) The dosage form of claim 117, wherein the plasma half-life of the at least one second

P24615.A17

drug differs from the plasma half-life of the first drug by at least about 2 hours.

129. (new) The dosage form of claim 118, wherein a plasma half-life of the at least one second drug differs from a plasma half-life of the first drug by at least about 3 hours.

130. (new) The dosage form of claim 117, wherein a plasma half-life of the at least one second drug differs from a plasma half-life of the first drug by at least about 4 hours.

131. (new) The dosage form of claim 128, wherein the period of a plasma concentration within the therapeutic range of the at least one second drug is coextensive with at least about 80 % of the period of a plasma concentration within the therapeutic range of the first drug.

132. (new) The dosage form of claim 117, wherein the period of a plasma concentration within the therapeutic range of the at least one second drug is coextensive with at least about 90 % of the period of a plasma concentration within the therapeutic range of the first drug.

133. (new) The dosage form of claim 130, wherein the period of a plasma concentration within the therapeutic range of the at least one second drug is coextensive with at least about 95 % of the period of a plasma concentration within the therapeutic range of the first drug.

134. (new) The dosage form of claim 117, wherein not more than about 30 % of a total period

P24615.A17

over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

135. (new) The dosage form of claim 132, wherein not more than about 20 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

136. (new) The dosage form of claim 131, wherein not more than about 10 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

137. (new) The dosage form of claim 118, wherein the dosage form comprises a tablet.

138. (new) The dosage form of claim 137, wherein the tablet is a bi-layered tablet.

139. (new) The dosage form of claim 137, wherein the tablet comprises a matrix which comprises the first drug and has dispersed therein particles which comprise the at least one second drug.

P24615.A17

140. (new) A bi-layered tablet which comprises a first layer and a second layer, the first layer comprising a first drug which comprises at least one morphine derivative having antitussive activity, and the second layer comprising at least one second drug which is selected from decongestants, expectorants, mucus thinning drugs, and antihistamines, wherein the bi-layered tablet provides a plasma concentration within a therapeutic range of the at least one second drug over a period which is coextensive with at least about 80 % of a period over which the bi-layered tablet provides a plasma concentration within a therapeutic range of the first drug.

141. (new) The dosage form of claim 140, wherein not more than about 20 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

142. (new) The bi-layered tablet of claim 140, wherein the first layer comprises at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof.

143. (new) The bi-layered tablet of claim 142, wherein the second layer comprises at least one of phenylephrine, pseudoephedrine, chlorpheniramine, carbinoxamine, promethazine, guaifenesin and pharmaceutically acceptable salts thereof.

144. (new) The bi-layered tablet of claim 141, wherein the tablet comprises at least two of

P24615.A17

phenylephrine, pseudoephedrine, chlorpheniramine, carbinoxamine, promethazine, guaifenesin and pharmaceutically acceptable salts thereof.

145. (new) The bi-layered tablet of claim 140, wherein the first layer only comprises one or more of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof as active ingredient(s).

146. (new) The bi-layered tablet of claim 140, wherein the period of a plasma concentration within the therapeutic range of the at least one second drug is coextensive with at least about 90 % of the period of a plasma concentration within the therapeutic range of the first drug.

147. (new) The bi-layered tablet of claim 140, wherein not more than about 10 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

148. (new) The bi-layered tablet of claim 140, wherein at least one of the first and second layers is an immediate release layer.

149. (new) The bi-layered tablet of claim 148, wherein the first layer is an immediate release layer.

P24615.A17

150. (new) The bi-layered tablet of claim 140, wherein both of the first and second layers are controlled release layers.

151. (new) The bi-layered tablet of claim 149, wherein the first layer comprises a total of from about 0.1 mg to about 120 mg of at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof.

152. (new) The bi-layered tablet of claim 140, wherein the first layer comprises a total of from about 5 mg to about 90 mg of at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof.

153. (new) The bi-layered tablet of claim 151, wherein the first layer comprises a total of from about 25 mg to about 50 mg of at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof.

154. (new) The bi-layered tablet of claim 152, wherein the second layer comprises at least one of (i) from about 0.1 mg to about 16 mg of chlorpheniramine maleate or an equivalent amount of at least one other pharmaceutically acceptable salt of chlorpheniramine; (ii) from about 1 mg to about 90 mg of phenylephrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of phenylephrine; (iii) from about 1 mg to about 240 mg of pseudoephedrine hydrochloride or an equivalent amount of at least one other pharmaceutically

P24615.A17

acceptable salt of pseudoephedrine; (iv) from about 0.1 mg to about 75 mg of promethazine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of promethazine; (v) from about 0.1 mg to about 32 mg of carbinoxamine maleate or an equivalent amount of at least one other pharmaceutically acceptable salt of carbinoxamine; and (vi) from about 1 mg to about 2400 mg of guaifenesin or an equivalent amount of at least one pharmaceutically acceptable salt of guaifenesin.

155. (new) The bi-layered tablet of claim 140, wherein the tablet comprises at least one of (i) from about 1 mg to about 90 mg of phenylephrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of phenylephrine; and (ii) from about 1 mg to about 240 mg of pseudoephedrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of pseudoephedrine, and the second layer comprises at least one of an antihistamine and an expectorant.

156. (new) The bi-layered tablet of claim 151, wherein not more than about 20 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

157. (new) The bi-layered tablet of claim 152, wherein not more than about 10 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is



P24615.A17

outside the period over which the plasma concentration of the first drug is within the therapeutic range.

158. (new) The bi-layered tablet of claim 154, wherein not more than about 10 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

159. (new) A pharmaceutical dosage form which comprises (a) a first drug which comprises at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof and has a first plasma half-life and (b) at least one second drug which is selected from decongestants, expectorants, mucus thinning drugs, and antihistamines and has a second plasma half-life which differs from the first plasma half-life by at least about 3 hours, wherein the dosage form provides a plasma concentration within a therapeutic range of the at least one second drug over a period which is coextensive with at least about 80 % of a period over which the dosage form provides a plasma concentration within a therapeutic range of the first drug.

160. (new) The dosage form of claim 159, wherein not more than about 10 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

P24615.A17

161. (new) The dosage form of claim 159, wherein the period of a plasma concentration within the therapeutic range of the at least one second drug is coextensive with at least about 90 % of the period over which the dosage form provides a plasma concentration within the therapeutic range of the first drug.

162. (new) The dosage form of claim 161, wherein not more than about 5 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

163. (new) The dosage form of claim 159, wherein the dosage form comprises a multi-layered tablet.

164. (new) The dosage form of claim 159, wherein the dosage form is associated with instructions to administer the dosage form three or fewer times per day.

165. (new) The dosage form of claim 117, wherein the dosage form is associated with instructions to administer the dosage form once or twice per day.

166. (new) A pharmaceutical dosage form which comprises (a) at least one first morphine derivative in a first form or layer and (b) at least one second morphine derivative which is different

P24615.A17

from the first morphine derivative in a second form or layer which is different from the first form or layer, wherein the dosage form releases the at least one first morphine derivative at least one of over a different period and at a different rate than the at least one second morphine derivative.

167. (new) The dosage form of claim 166, wherein the at least one first morphine derivative and the at least one second morphine derivative are independently selected from codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts thereof.

168. (new) The dosage form of claim 167, wherein the at least one first morphine derivative and the at least one second morphine derivative comprise at least one of codeine phosphate, dihydrocodeine bitartrate and hydrocodone bitartrate.

169. (new) The dosage form of claim 166, wherein the dosage form comprises codeine phosphate.

170. (new) The dosage form of claim 167, wherein the first form or layer is an immediate release form or layer and the second form or layer is a controlled release form or layer.

171. (new) The dosage form of claim 166, wherein the dosage form is a bi-layered tablet which comprises an immediate release layer and a controlled release layer, which layers independently comprise at least one of codeine, dihydrocodeine, hydrocodone and pharmaceutically acceptable salts

P24615.A17

thereof.

172. (new) The dosage form of claim 171, wherein the dosage form further comprises at least one additional drug which is selected from decongestants, expectorants, mucus thinning drugs, and antihistamines.

173. (new) The dosage form of claim 171, wherein at least the immediate release layer thereof comprises the at least one additional drug.

174. (new) The dosage form of claim 171, wherein at least the controlled release layer thereof comprises the at least one additional drug.

175. (new) The dosage form of claim 166, wherein the dosage form releases the at least one first morphine derivative over a different period and at a different rate than the at least one second morphine derivative.

176. (new) The dosage form of claim 175, wherein the dosage form releases the at least one first morphine derivative over a different period than the at least second morphine derivative.

177. (new) The dosage form of claim 175, wherein the dosage form releases the at least one first morphine derivative over a first period and the at least one second morphine derivative over a second

P24615.A17

period and not more than about 30 % of the second period are coextensive with all or a part of the first period.

178. (new) The dosage form of claim 177, wherein there is substantially no overlap between the first and second periods.

179. (new) The dosage form of claim 166, wherein the dosage form releases the at least one first morphine derivative at a different rate than the at least second morphine derivative.

180. (new) A bi-layered tablet which comprises a first layer and a second layer, the first layer comprising a first drug which is selected from codeine and pharmaceutically acceptable salts thereof, and the second layer comprising at least one second drug which is selected from decongestants, expectorants, mucus thinning drugs, and antihistamines, wherein the bi-layered tablet provides a plasma concentration within a therapeutic range of the at least one second drug over a period which is coextensive with at least about 70 % of a period over which the bi-layered tablet provides a plasma concentration within a therapeutic range of the first drug.

181. (new) The bi-layered tablet of claim 180, wherein the first layer comprises codeine phosphate.

182. (new) The bi-layered tablet of claim 181, wherein the second layer comprises at least one of

P24615.A17

phenylephrine, pseudoephedrine, chlorpheniramine, carbinoxamine, promethazine, guaifenesin and pharmaceutically acceptable salts thereof.

183. (new) The bi-layered tablet of claim 181, wherein the tablet comprises at least two of phenylephrine, pseudoephedrine, chlorpheniramine, carbinoxamine, promethazine, guaifenesin and pharmaceutically acceptable salts thereof.

184. (new) The bi-layered tablet of claim 180, wherein the first layer comprises only one or more of codeine and pharmaceutically acceptable salts thereof as active ingredient(s).

185. (new) The bi-layered tablet of claim 180, wherein the period of a plasma concentration within the therapeutic range of the at least one second drug is coextensive with at least about 80 % of the period of a plasma concentration within the therapeutic range of the first drug.

186. (new) The bi-layered tablet of claim 184, wherein the period of a plasma concentration within a therapeutic range of the at least one second drug is coextensive with at least about 90 % of the period of a plasma concentration within a therapeutic range of the first drug.

187. (new) The bi-layered tablet of claim 180, wherein not more than about 20 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic

P24615.A17

range.

188. (new) The bi-layered tablet of claim 185, wherein not more than about 20 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

189. (new) The bi-layered tablet of claim 186, wherein not more than about 10 % of a total period over which the plasma concentration of the at least one second drug is within the therapeutic range is outside the period over which the plasma concentration of the first drug is within the therapeutic range.

190. (new) The bi-layered tablet of claim 180, wherein at least one of the first and second layers is an immediate release layer.

191. (new) The bi-layered tablet of claim 191, wherein the first layer is an immediate release layer.

192. (new) The bi-layered tablet of claim 190, wherein the second layer is an immediate release layer.

193. (new) The bi-layered tablet of claim 180, wherein both of the first and second layers are

P24615.A17

controlled release layers.

194. (new) The bi-layered tablet of claim 180, wherein the first layer comprises a total of from about 5 mg to about 90 mg of at least one of codeine and a pharmaceutically acceptable salt thereof.

195. (new) The bi-layered tablet of claim 180, wherein the first layer comprises a total of from about 25 mg to about 50 mg of at least one of codeine phosphate.

196. (new) The bi-layered tablet of claim 195, wherein the second layer comprises at least one of (i) from about 0.1 mg to about 16 mg of chlorpheniramine maleate or an equivalent amount of at least one other pharmaceutically acceptable salt of chlorpheniramine; (ii) from about 1 mg to about 90 mg of phenylephrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of phenylephrine; (iii) from about 1 mg to about 240 mg of pseudoephedrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of pseudoephedrine; (iv) from about 0.1 mg to about 75 mg of promethazine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of promethazine; (v) from about 0.1 mg to about 32 mg of carbinoxamine maleate or an equivalent amount of at least one other pharmaceutically acceptable salt of carbinoxamine; and (vi) from about 1 mg to about 2400 mg of guaifenesin or an equivalent amount of at least one pharmaceutically acceptable salt of guaifenesin.



P24615.A17

197. (new) The bi-layered tablet of claim 195, wherein the first layer comprises at least one of (i) from about 1 mg to about 90 mg of phenylephrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of phenylephrine; and (ii) from about 1 mg to about 240 mg of pseudoephedrine hydrochloride or an equivalent amount of at least one other pharmaceutically acceptable salt of pseudoephedrine, and the second layer comprises at least one of an antihistamine and an expectorant.

198. (new) The dosage form of claim 120, wherein the second drug comprises at least one drug selected from phenylephrine, pseudoephedrine and pharmaceutically acceptable salts thereof.

199. (new) The dosage form of claim 120, wherein the at least one second drug comprises at least one drug selected from chlorpheniramine, promethazine, carbinoxamine and pharmaceutically acceptable salts thereof.

200. (new) The dosage form of claim 120, wherein the at least one second drug comprises guaifenesin.